Author: Sarah Collins

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

Johnson & Johnson started shipments of its revamped baby care line in July, which is expected to register improved performance in the third quarter.

On September 28, UnitedHealth Group (UNH) announced the acquisition of pharmacy company Genoa Healthcare for nearly $2.5 billion from Advent International.

Johnson & Johnson is scheduled to report its Q2 2018 earnings results on July 17. The company expects to register improved sales performance at its consumer business segment.

On June 28, UnitedHealth Group (UNH) ended the trading day at $244.90, ~4.6% lower than its 52-week low of $183.86 reached on July 18, 2017.

Today, CVS Health, the leading pharmacy benefit managers, is up ~5% after announcing the launch of its drug delivery service from all of its US locations.

In 1Q18, Teva Pharmaceutical Industries (TEVA) recorded non-GAAP (generally accepted accounting principles) EPS (earnings per share) of $0.94 and net income of $954 million.

Pfizer (PFE) has been looking to sell its consumer health business since October 2017.

On February 15, TEVA stock rose ~10.5% in pre-market trading on the disclosure of Berkshire Hathaway's investment of $358 million in the stock at the end of 4Q17.

On December 28, 2017, Align Technology (ALGN) was the top-performing stock in the S&P 500. ALGN has generated an ~130.0% return during the past year.

On December 4, 2017, Leerink Swann reaffirmed its "outperform" rating on Thermo Fisher Scientific (TMO). It decreased its target price on TMO stock from $216.00 per share to $200.00 per share.